3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Common Variable Immunodeficiency
1
Agammaglobulinemia
1
Interventions
Cyclophosphamide
29
Rituximab
24
fludarabine
15
fludarabine phosphate
13
Specimen Handling
12
obinutuzumab
10
ibrutinib
10
Magnetic Resonance Spectroscopy
10
Prednisone
9
Doxorubicin
9
Mycophenolic Acid
8
Etoposide
8
tocilizumab
7
polatuzumab vedotin
7
X-Rays
7
Whole-Body Irradiation
7
Phantoms, Imaging
7
Lenalidomide
7
Biopsy
7
venetoclax
6
glofitamab
6
Vincristine
6
Melphalan
6
Busulfan
6
Bendamustine Hydrochloride
6
pirtobrutinib
5
acalabrutinib
5
Peripheral Blood Stem Cell Transplantation
5
Nuclear Medicine Department, Hospital
5
Nivolumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Non-Hodgkin
×
Hizentra
×
90 days
×
Clear all
NCT07582432
2026-05-12
SIGMA
Grifols Biologicals, LLC
Phase 3
Recruiting
49 enrolled